A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors

Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated dose (MTD) of 60 mg/m(2) daily for 4 days in children with recurrent/refractory neuroblastoma. We report additional results of a Phase 1 trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Bishop, Michael W., Hutson, Paul R., Hank, Jacquelyn A., Sondel, Paul M., Furman, Wayne L., Meagher, Michael M., Navid, Fariba, Santana, Victor M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531516/
https://www.ncbi.nlm.nih.gov/pubmed/32643524
http://dx.doi.org/10.1080/19420862.2020.1773751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531516/
https://www.ncbi.nlm.nih.gov/pubmed/32643524
http://dx.doi.org/10.1080/19420862.2020.1773751

Ejemplares similares